These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 22494466)

  • 101. Enzymatic stimulation and enzymatic inhibition in Parkinson's disease.
    Nagatsu T
    Acta Neurol Scand Suppl; 1993; 146():14-7. PubMed ID: 8101411
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease.
    Perez-Lloret S; Otero-Losada M; Toblli JE; Capani F
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1163-1173. PubMed ID: 28836869
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Evaluating drug treatments for Parkinson's disease: how good are the trials?
    Wheatley K; Stowe RL; Clarke CE; Hills RK; Williams AC; Gray R
    BMJ; 2002 Jun; 324(7352):1508-11. PubMed ID: 12077043
    [No Abstract]   [Full Text] [Related]  

  • 104. Management of response fluctuations: practical guidelines.
    Djaldetti R; Melamed E
    Neurology; 1998 Aug; 51(2 Suppl 2):S36-40. PubMed ID: 9711979
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Neuroprotective approaches to halt Parkinson's disease progression.
    Sola P; Krishnamurthy PT; Kumari M; Byran G; Gangadharappa HV; Garikapati KK
    Neurochem Int; 2022 Sep; 158():105380. PubMed ID: 35718278
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Rational drug discovery design approaches for treating Parkinson's disease.
    Van der Schyf CJ
    Expert Opin Drug Discov; 2015 Jul; 10(7):713-41. PubMed ID: 26054694
    [TBL] [Abstract][Full Text] [Related]  

  • 107. [Pharmacological treatment of motor symptoms in Parkinson's diseases].
    Jost WH
    Nervenarzt; 2017 Apr; 88(4):373-382. PubMed ID: 28289795
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Advances in drug development for Parkinson's disease: present status.
    Harikrishna Reddy D; Misra S; Medhi B
    Pharmacology; 2014; 93(5-6):260-71. PubMed ID: 25096413
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Development of Prodrugs for Treatment of Parkinson's Disease: New Inorganic Scaffolds for Blood-Brain Barrier Permeation.
    Di Battista V; Hey-Hawkins E
    J Pharm Sci; 2022 May; 111(5):1262-1279. PubMed ID: 35182542
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease.
    You H; Mariani LL; Mangone G; Le Febvre de Nailly D; Charbonnier-Beaupel F; Corvol JC
    Cell Tissue Res; 2018 Jul; 373(1):111-135. PubMed ID: 29516217
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Potential transbuccal delivery of l-DOPA methylester prodrug: stability in the environment of the oral cavity and ability to cross the mucosal tissue.
    Scaturro AL; De Caro V; Campisi G; Giannola LI
    Drug Deliv; 2016 Sep; 23(7):2355-2362. PubMed ID: 25533875
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Glycosyl derivatives of dopamine and L-dopa as anti-Parkinson prodrugs: synthesis, pharmacological activity and in vitro stability studies.
    Bonina F; Puglia C; Rimoli MG; Melisi D; Boatto G; Nieddu M; Calignano A; La Rana G; De Caprariis P
    J Drug Target; 2003 Jan; 11(1):25-36. PubMed ID: 12852438
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Phosphoramidate derivates as controlled-release prodrugs of l-Dopa.
    Olatunji FP; Kesic BN; Choy CJ; Berkman CE
    Bioorg Med Chem Lett; 2019 Sep; 29(18):2571-2574. PubMed ID: 31400939
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Istradefylline for the treatment of Parkinson's disease.
    Park A; Stacy M
    Expert Opin Pharmacother; 2012 Jan; 13(1):111-4. PubMed ID: 22149371
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Antiparkinsonian drugs and their neuroprotective effects.
    Kitamura Y; Kakimura J; Taniguchi T
    Biol Pharm Bull; 2002 Mar; 25(3):284-90. PubMed ID: 11913520
    [TBL] [Abstract][Full Text] [Related]  

  • 116. [The development of therapeutic agents for Parkinson's disease and problems in their clinical application].
    Murata M
    Nihon Yakurigaku Zasshi; 2008 Apr; 131(4):281-4. PubMed ID: 18408339
    [No Abstract]   [Full Text] [Related]  

  • 117. Medical treatment of Parkinson's disease: today and the future.
    Gárdián G; Vécsei L
    Int J Clin Pharmacol Ther; 2010 Oct; 48(10):633-42. PubMed ID: 20875369
    [TBL] [Abstract][Full Text] [Related]  

  • 118. A Novel Iron(II) Preferring Dopamine Agonist Chelator as Potential Symptomatic and Neuroprotective Therapeutic Agent for Parkinson's Disease.
    Das B; Kandegedara A; Xu L; Antonio T; Stemmler T; Reith MEA; Dutta AK
    ACS Chem Neurosci; 2017 Apr; 8(4):723-730. PubMed ID: 28106982
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Emerging therapies in the pharmacological treatment of Parkinson's disease.
    Korczyn AD; Nussbaum M
    Drugs; 2002; 62(5):775-86. PubMed ID: 11929331
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Parkinson's Disease: A Review from Pathophysiology to Treatment.
    Marino BLB; de Souza LR; Sousa KPA; Ferreira JV; Padilha EC; da Silva CHTP; Taft CA; Hage-Melim LIS
    Mini Rev Med Chem; 2020; 20(9):754-767. PubMed ID: 31686637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.